CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization